Suppr超能文献

利用发光铽(III)配合物对蛋白酪氨酸激酶和磷酸酶抑制剂进行无共轭、可视化和定量评估。

Conjugation-free, visual, and quantitative evaluation of inhibitors on protein tyrosine kinases and phosphatases with a luminescent Tb(III) complex.

作者信息

Akiba Hiroki, Sumaoka Jun, Hamakubo Takao, Komiyama Makoto

机构信息

Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Meguro-ku, Tokyo, 153-8904, Japan.

出版信息

Anal Bioanal Chem. 2014 May;406(12):2957-64. doi: 10.1007/s00216-014-7707-x. Epub 2014 Mar 21.

Abstract

A straightforward and visual method to assess inhibitors on protein tyrosine kinases (PTKs) and phosphatases (PTPs) has been developed. These enzymes play critical roles in a number of diseases and, thus, their inhibitors are important for effective therapy. With the use of the long-life luminescence emitted from a binuclear Tb(III) complex, enzymatic reactions of PTKs and PTPs were monitored in real-time, and the inhibitor activity was quantitatively evaluated in terms of the decrease in the rate of luminescence change. No conjugation of the probe to a substrate peptide was necessary. The IC50 values of four inhibitors on three kinds of PTKs [Src, Fyn, and epidermal growth factor receptor (EGFR)] were determined. For example, gefitinib, which is a selective inhibitor on EGFR, inhibited this PTK with IC50 of 22 nM. Towards Src and Fyn (non-targeted PTK), however, IC50 of this inhibitor was greater than 20 μM as expected. Inhibition of two kinds of PTPs (Shp-1 and PTP1B) by two inhibitors was also assayed, providing completely consistent results on their known selectivity. Furthermore, the system where both PTK and PTP are active was monitored and the reactions were visualized with the present Tb(III) complex-based method. High potential of the present method to a variety of systems has been evidenced.

摘要

已开发出一种直接且直观的方法来评估蛋白酪氨酸激酶(PTK)和蛋白酪氨酸磷酸酶(PTP)的抑制剂。这些酶在多种疾病中发挥关键作用,因此它们的抑制剂对有效治疗很重要。利用双核Tb(III)配合物发出的长寿命发光,实时监测PTK和PTP的酶促反应,并根据发光变化速率的降低对抑制剂活性进行定量评估。无需将探针与底物肽缀合。测定了四种抑制剂对三种PTK[Src、Fyn和表皮生长因子受体(EGFR)]的IC50值。例如,吉非替尼是EGFR的选择性抑制剂,其抑制该PTK的IC50为22 nM。然而,对于Src和Fyn(非靶向PTK),该抑制剂的IC50如预期大于20 μM。还检测了两种抑制剂对两种PTP(Shp-1和PTP1B)的抑制作用,在其已知选择性方面提供了完全一致的结果。此外,监测了PTK和PTP均有活性的系统,并使用基于Tb(III)配合物的现有方法对反应进行了可视化。已证明本方法对各种系统具有很高的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验